Brought to you by 
Quintiles buys Targeted Molecular Diagnostics
04 Dec 2008
Executive Summary
Global CRO Quintiles Transnational is expanding its oncology offerings through the acquisition of biomarker discovery company Targeted Molecular Diagnostics (TMD).
Deal Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Quintiles buys Targeted Molecular Diagnostics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice